Once-Weekly Semaglutide 7.2 mg Beats Placebo for Obesity
Second study shows 7.2 mg semaglutide leads to greater reductions in mean body weight for those with obesity, T2D
Skin Cancer Risk Reduced for Patients Treated With Nicotinamide
Greatest effect was seen when nicotinamide was initiated after the first skin cancer
Few Adults With Dry Eye Diagnosed, Treated
70 percent of participants lacked knowledge of treatment options; 67 percent waited six months or longer to see an eye care provider
Alcohol-Induced Deaths Almost Doubled From 1999 to 2024
Largest increase seen in women aged 25 to 34 years
Digital Intervention Aids Psychological Outcomes With Inflammatory Rheumatic Diseases
Clinically significant reduction in psychological distress seen at three months with digital intervention
DermaRite Widens Recall to 32 Products Over Bacteria Risk
Recalled items include body washes, lotions, soaps, shampoos, sanitizers and wound cleansers sold nationwide and in Puerto Rico
FDA Cracks Down on Hims, Other Telehealth Companies Over Drug Ads
Hims was flagged for misleading claims about compounded Ozempic/Wegovy
Over-the-Counter Naloxone Shows Limited Uptake
Sales are a fraction of pharmacy-dispensed and program-distributed naloxone
Without Biannual Time Shift, Prevalence of Obesity, Stroke May Be Reduced
Modeling study shows decrease in prevalence of both obesity and stroke under Standard Time, Daylight Saving Time versus current policy
GLP-1 RAs Cost-Effective Versus Usual Care for Knee OA, Obesity
Tirzepatide offers more favorable return on investment, but greater benefits seen at lower costs for Roux-en-Y gastric bypass
